Displaying 37 - 48 of 136
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
8

Sanofi: Reducing the burden of liver disease - new evidence revealed - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Displaying 37 - 48 of 136